Maureen Canavan, PhD, MPH
Associate Research Scientist (General Medicine)Cards
About
Titles
Associate Research Scientist (General Medicine)
Affiliated Faculty, Yale Institute for Global Health
Biography
Maureen E. Canavan, Ph.D., is an epidemiologist at Yale Cancer Outcomes, Public Policy and Effectiveness Research Center (COPPER) since 2017. In addition to working the MCBS data, she works as part of the Yale Cancer Center’s Cancer Care Innovations Lab (CaCIL) team evaluating quality metrics for cancer care. Her research interests include health management, employment, and end of life care. Prior to her work at COPPER, she was a member of the Global Health Leadership Institute (GHLI) team, she conducts qualitative and quantitative data analysis of GHLI studies in countries including Ghana, Ethiopia and China. She received an M.P.H. from the University of Medicine and Dentistry of New Jersey, School of Public Health and a B.S. from Pennsylvania State University.
Last Updated on May 21, 2025.
Appointments
General Internal Medicine
Associate Research ScientistPrimary
Other Departments & Organizations
- COPPER Center
- General Internal Medicine
- Internal Medicine
- Obesity Research Working Group
- Yale Institute for Global Health
Education & Training
- PhD
- Yale University Graduate School (2011)
- MPH
- University of Medicine and Dentistry of New Jersey, School of Public Health, Epidemiology, Health Education, and Behavioral Science (2005)
- BS
- Pennsylvania State University, Biology (2003)
Research
Publications
2026
Response to neoadjuvant chemoimmunotherapy in EGFR- or ALK-mutated non-small cell lung cancer.
Caturegli G, Jernigan E, Canavan M, Lynch A, Patil J, Resio B, Boffa D. Response to neoadjuvant chemoimmunotherapy in EGFR- or ALK-mutated non-small cell lung cancer. Journal Of Clinical Oncology 2026, 44: 8054-8054. DOI: 10.1200/jco.2026.44.16_suppl.8054.Peer-Reviewed Original ResearchWild-type patientsNeoadjuvant chemoimmunotherapyNodal downstagingLung cancerALK mutationsStage I-III NSCLCTreated with neoadjuvant chemoimmunotherapyNon-small cell lung cancerMutation-targeted therapiesCharlson-Deyo scoreComplete pathologic responsePathological complete responseHigh tumor gradeCell lung cancerYear of diagnosisAssociated with significantly higher oddsRate of pCRLack of efficacyMultivariate logistic regressionSignificantly higher oddsEGFR/ALK mutationsKIF5B-ALKNeoadjuvant immunotherapyTFG-ALKPCR rateUnderstanding the role of large language models in cancer mortality prediction: A real-world study.
Peng X, Canavan M, He H, Westvold S, Qian L, Gross C, Huntington S, Xu H. Understanding the role of large language models in cancer mortality prediction: A real-world study. Journal Of Clinical Oncology 2026, 44: e23177-e23177. DOI: 10.1200/jco.2026.44.16_suppl.e23177.Peer-Reviewed Original ResearchElectronic health recordsLogistic regressionIndex visitYale New Haven HealthArea under the receiver operating characteristic curveMortality predictionClinical decision supportHeterogeneous cancer populationStructured EHR dataLonger-term mortalityDay of deathHealth recordsFollow-upRetrospective cohort studyEHR dataComorbidity codesCancer populationMortality risk predictionCancer diagnosisPredictive of mortalityCohort studyPatient characteristicsRisk predictionVisitsRisk determinantsHigh‐Risk Medication Prescribing Among Older Adults in the Emergency Department: A National Assessment
Follman S, Canavan M, Rothenberg C, Iscoe M, Venkatesh A, Ramachandran R, Gettel C. High‐Risk Medication Prescribing Among Older Adults in the Emergency Department: A National Assessment. Academic Emergency Medicine 2026, 33: e70321. PMID: 42136546, DOI: 10.1111/acem.70321.Peer-Reviewed Original ResearchConceptsDays of ED dischargeED dischargeOlder adultsMedication fillsMedication prescribingED visitsYounger cohorts of older adultsCohort of older adultsTransitions of careHigh-risk medicationsAssociated with higher oddsSystem-level factorsAdverse drug eventsCross-sectional studyYounger cohortsDays of dischargeMultivariate logistic regressionMedication safetyED encountersTargeted educationDrug eventsHigher oddsEmergency departmentSkeletal muscle relaxantsMedication classesCounty-Level Structural Racism Indices and Racial Disparities in Lung Cancer Care
Gaddy J, Lee D, Herrin J, Yu J, Pollack C, Dean L, Dougherty G, Canavan M, Soulos P, Gross C. County-Level Structural Racism Indices and Racial Disparities in Lung Cancer Care. JAMA Network Open 2026, 9: e2613919. PMID: 42160049, PMCID: PMC13191378, DOI: 10.1001/jamanetworkopen.2026.13919.Peer-Reviewed Original ResearchThis study investigates how structural racism at the county level impacts racial disparities in lung cancer care, showing worse outcomes for Black patients compared to white patients, especially in areas with higher structural racism.RF77. The Prognosis of Single-site Oligometastatic Non-Small Cell Lung Cancer Treated with Local Therapies in the Era of Immunotherapy
Esnaola G, Canavan M, Caturegli G, Lynch A, Resio B. RF77. The Prognosis of Single-site Oligometastatic Non-Small Cell Lung Cancer Treated with Local Therapies in the Era of Immunotherapy. Journal Of Thoracic And Cardiovascular Surgery 2026, 171: s162-s163. DOI: 10.1016/j.jtcvs.2026.03.525.Peer-Reviewed Original ResearchReal-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer
Caturegli G, Canavan M, Ayoade O, Boffa D, Resio B. Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer. Clinical Lung Cancer 2026, 27: 48-54.e2. PMID: 42070908, DOI: 10.1016/j.cllc.2026.03.016.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage III non-small cell lung cancerIII non-small cell lung cancerStage III NSCLC patientsThree-year overall survivalIII NSCLC patientsStage III patientsOutcome of radiationOverall survivalNSCLC patientsIII patientsRadiation patientsNonsurgical optionsLung cancerClinical stage III patientsStage III lung cancerIII lung cancerNational Cancer DatabaseReal-world outcomesCell lung cancerKaplan-Meier curvesStandard treatment approachTotal radiation doseAlternative nonsurgical optionNeoadjuvant chemoimmunotherapyReal-world period prevalence of psoriatic disease 2015-2025: A cross-sectional study in the Epic Cosmos database
Lee M, Canavan M, Cohen J. Real-world period prevalence of psoriatic disease 2015-2025: A cross-sectional study in the Epic Cosmos database. Journal Of The American Academy Of Dermatology 2026, 95: 181-183. PMID: 41903709, DOI: 10.1016/j.jaad.2026.03.067.Peer-Reviewed Original ResearchUpdated Review: Using the National Cancer Database for Outcomes-Based Research.
Ayoade O, Caturegli G, Palis B, McCabe R, Weigel R, Canavan M, Boughey J, Boffa D. Updated Review: Using the National Cancer Database for Outcomes-Based Research. Journal Of The American College Of Surgeons 2026 PMID: 41848188, DOI: 10.1097/xcs.0000000000001924.Peer-Reviewed Original ResearchNational Cancer DatabaseFollow-upNon-small cell lung cancerAmerican CollegeCell lung cancerNarrative reviewCancer Reporting SystemCancer-accredited hospitalsPD-L1Tumor gradeTumor sizeCancer DatabaseContinuous tumor sizeLung cancerSmoking statusOutcomes-based researchOncology practiceSurvival dataMedicaid expansion statusOutcome studiesFollow-up limitCancerTreatment reportsPolicy changesPolicy-relevant dataUse of Complementary and Alternative Medicine in the Management of Breast Cancer
Ayoade O, Caturegli G, Canavan M, Resio B, Berger E, Boffa D. Use of Complementary and Alternative Medicine in the Management of Breast Cancer. JAMA Network Open 2026, 9: e260337. PMID: 41770560, PMCID: PMC12954545, DOI: 10.1001/jamanetworkopen.2026.0337.Peer-Reviewed Original ResearchConceptsCohort studyManagement of breast cancerBreast cancerCohort study of dataMedical management of breast cancerTreated with CAMCox proportional hazards modelsMedical managementYear of diagnosisFemale patientsCombination of CAMProportional hazards modelTraditional therapiesAlternative medicineStudy of dataMain OutcomesEndocrine therapyNo treatmentCharlson Comorbidity IndexInsurance typeNonmedical personnelPrimary outcomeFacility typeSurvival timeHazards model
2025
Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality
Canavan M, Cheng L, Xiang J, Lin J, Hui D, Zhao H, Nortje N, Ratan R, Cherny N, Pham T, Giordano S, Niu J, Adelson K. Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality. Journal Of Clinical Oncology 2025, 43: 3391-3402. PMID: 41004691, DOI: 10.1200/jco-25-00530.Peer-Reviewed Original ResearchThis study investigates the impact of systemic anticancer therapy near the end of life on healthcare and hospice for older adults, showing increased acute care utilization and decreased hospice use, highlighting the need for improved end-of-life care guidelines.
Academic Achievements & Community Involvement
News
News
- January 08, 2026Source: JCO Podcast
Podcast: Association Between EOL SACT and Healthcare Utilization
- October 22, 2025Source: Cure
Improving End-of-Life Care: Making Hospice and Home Support Accessible
- May 28, 2025
United by Cancer Research: One Mission. One Voice
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO